[Pharmacogenetic contribution to individualized treatment. Severe adverse effects can be avoided].
Eliasson
Erik
E
Klinisk farmakologi, institutionen för laboratoriemedicin, Karolinska institutet. erik.eliasson@ki.se
D015224:Dideoxynucleosides / Q000008:administration & dosage / Q000009:adverse effects; D004342:Drug Hypersensitivity / Q000209:etiology / Q000235:genetics / Q000276:immunology; D064420:Drug-Related Side Effects and Adverse Reactions; D015235:HLA-B Antigens / Q000235:genetics; D006801:Humans; D004364:Pharmaceutical Preparations / Q000008:administration & dosage; D010597:Pharmacogenetics; D012307:Risk Factors; D012449:Safety; D000099227:Abacavir
D015224:Dideoxynucleosides; D015235:HLA-B Antigens; D004364:Pharmaceutical Preparations; D000099227:Abacavir; C484830:HLA-B*57:01 antigen